The effect of bromelain capsules on stress and depressive anxiety in diabetic foot ulcer patients

The effect of bromelain capsule on stress, anxiety , depression in patients with diabetic foot ulcer

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190708044148N2

Enrollment

Registered

2022-04-26

Start date

2022-04-09

Completion date

Unknown

Last updated

2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic foot ulcer. Type 1 diabetes mellitus with circulatory complications

Interventions

Intervention 1: Intervention group: Intervention group Bromilin capsules containing 200 mg of this substance (500 GDU) made by Permon Amin Company twice daily (once in the morning before breakfast and

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Age 18 to 60 years Informed consent Mild or moderate score in DASS-21 pre-test

Exclusion criteria

Exclusion criteria: The patient is taking drugs that interact with bromelain Patients enrolled in other clinical trial studies History of other wounds

Design outcomes

Primary

Measure	Time frame
Stress. Timepoint: Measurements before the study and 4 weeks after the start of the intervention. Method of measurement: Depression, Anxiety and Stress Questionnaire (DASS-21).;Anxiety. Timepoint: Measurements before the study and 4 weeks after the start of the intervention. Method of measurement: Depression, Anxiety and Stress Questionnaire (DASS-21).;Depression. Timepoint: Measurements before the study and 4 weeks after the start of the intervention. Method of measurement: Depression, Anxiety and Stress Questionnaire (DASS-21).	—

Measure

Time frame

Stress. Timepoint: Measurements before the study and 4 weeks after the start of the intervention. Method of measurement: Depression, Anxiety and Stress Questionnaire (DASS-21).;Anxiety. Timepoint: Measurements before the study and 4 weeks after the start of the intervention. Method of measurement: Depression, Anxiety and Stress Questionnaire (DASS-21).;Depression. Timepoint: Measurements before the study and 4 weeks after the start of the intervention. Method of measurement: Depression, Anxiety and Stress Questionnaire (DASS-21).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlireza Salmani

Tehran University of Medical Sciences

Alirezasalmani192@gmail.com+98 28 3283 6289

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026